Advanced in Rheumatoid Arthritis (RA)

Ning-sheng Lai

Min Sheng Rd, 
Minsheng, KHQ, TW 
Advanced in Rheumatoid Arthritis (RA)
Min Sheng Rd, 
Minsheng, KHQ, TW 
OverviewLocationsClinical Research

Overview

Ning-sheng Lai practices in Minsheng, Taiwan. Lai is rated as an Advanced expert by MediFind in the treatment of Rheumatoid Arthritis (RA). Their top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus (SLE), and Hip Replacement.

Their clinical research consists of co-authoring 83 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 42 articles in the study of Rheumatoid Arthritis (RA).

Locations

Min Sheng Rd, Minsheng, KHQ 62247, Taiwan
Other Locations
No. 701, Zhongyang Road, Sec. 3, Hualien City 970374, Hualien City, TNQ 97037, Taiwan
Dalin, KHQ, Taiwan
Jiayi Shi, TNQ 62247, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

83 Total Publications

Glycoproteomics of IgA1: uncovering key N-glycan composition in ankylosing spondylitis.
Glycoproteomics of IgA1: uncovering key N-glycan composition in ankylosing spondylitis.
Journal: Glycobiology
Published: January 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lai's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile